Results 231 to 240 of about 341,593 (314)

International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR. [PDF]

J Clin Oncol
Alger E, Aiyegbusi OL, Dueck AC, Minchom A, Pe M, Peipert JD, Snyder C, Symeonides SN, Wilson R, Basch E, Qiao Y, Bates SE, Bulbeck H, Dean L, Di Maio M, Hansen AR, Kholmanskikh O, Kobayashi K, Landers D, Le Tourneau C, Lee JJ, Ma BBY, Marshall LV, Patel S, Petrie J, Pond GR, Prior K, Rantell KR, Reeve JF, Solovyeva O, Wages NA, Weber HA, Calvert MJ, Yap C.   +33 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Quantifying the Tolerability of Dopamine Agonist Antiparkinsonian Medication Side Effects: A Best-Worst Scaling Survey. [PDF]

Patient Prefer Adherence
Richards K, Avanceña ALV, Johnsrud M, Collier H, Mantri S, Yarbrough D, Subasinghe A, Sasané R, Arcona S.   +8 more
europepmc   +1 more source

Nanoparticle-mediated mRNA delivery for cancer, autoimmunity, and genetic diseases: a rapid review. [PDF]

Front Drug Deliv
Ugwu OP, Ogenyi FC, Basajja M, Ugwu CN, Mustafa MM, Okon MB.   +5 more
europepmc   +1 more source

Exposure, Extinction, and Cognitive Appraisals in Autistic Adults With Social Anxiety: Evidence From a Structured Speech Exposure Task

Autism Research, EarlyView.
ABSTRACT Social anxiety (SA) is highly prevalent among autistic adults, yet little is known about how autistic people respond to common therapeutic strategies, such as exposure tasks. This study examined responses to a structured speech exposure task embedded within an 8‐week modified cognitive–behavioral therapy (M‐CBT) program.
Bruna B. Roisenberg, Kelsie A. Boulton, Emma E. Thomas, Dorothy Yu, Adam J. Guastella   +4 more
wiley   +1 more source

Long-Term Effectiveness and Tolerability of Dolutegravir/Lamivudine in Korea: A 3-Year Follow Up Study. [PDF]

Infect Chemother
Seong JE, Ahn SM, Han M, Lee YS, Lee JA, Ahn JY, Jeong SJ, Ku NS, Choi JY, Yeom JS, Kim JH.   +10 more
europepmc   +1 more source

Bacterial Pigments as Potential Antitumor Agents Against Gastrointestinal Cancers: A Comprehensive Systematic Review

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Gastrointestinal cancers (GICs) constitute one of the leading causes of cancer‐related morbidity and mortality worldwide. Despite currently available therapeutic strategies, new approaches and procedures are needed for their prevention and treatment.
Raúl Vergara, Ricardo F. S. Pereira, Carla C. C. R. de Carvalho, Jose Prados, Consolación Melguizo, Raul Ortiz   +5 more
wiley   +1 more source

Variables associated with clinical outcomes and switching from unilateral to bitemporal electroconvulsive therapy: a retrospective study. [PDF]

Front Psychiatry
Sordo E, Fuet L, Porpiglia F, Zrelli M, Amagat M, De Maricourt P, Gaillard R, Smadja S, Vinckier F, Schimpf C, Tomberli F, Mazeraud A, Domenech P, Chalah MA.   +13 more
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Individualizing isotretinoin dosing in acne: comparable 24-week efficacy and better tolerability at lower daily doses. [PDF]

Front Med (Lausanne)
Zou J, Li Y, Wang L, Jiang Y, Fang F, Shao K, Zhang X, Zhu T, Yu X.   +8 more
europepmc   +1 more source